🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being hailed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts.

A Global Public Health Issue

Gonorrhoea infections are increasing around the world, with figures suggesting more than 82 million new cases annually. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. In England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely step in the context of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options at this time.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Clearance

Zoliflodacin, marketed under the name Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GlaxoSmithKline, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the drug firm its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Clinical Trial Results and Worldwide Availability

As per results detailed in a prominent scientific publication, zoliflodacin successfully treated over nine in ten of uncomplicated infections. This establishes an comparable level with the existing first-line therapy, which uses an injection and a pill. The research enrolled over 900 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, GARDP has the rights to register and commercialise the drug in a wide range of developing nations.

Clinicians treating patients have voiced optimism. The availability of a single-dose, oral treatment of this kind is seen as a "revolutionary step" for gonorrhoea control. This is deemed essential to alleviate the strain of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea around the world.